Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE